Unveiling the comorbidity burden of male breast cancer.
Breast cancer
Clinical characteristics
Clinical feature
Co-existing conditions
Comorbidity
Male breast cancer
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
03 10 2024
03 10 2024
Historique:
received:
16
04
2024
accepted:
12
09
2024
medline:
4
10
2024
pubmed:
4
10
2024
entrez:
3
10
2024
Statut:
epublish
Résumé
Male breast cancer (MBC) is a rare condition with unique characteristics compared to female breast cancer (FBC). Despite its scarceness, there is growing evidence that MBC should not be studied and treated as FBC due to factors like later diagnosis stage and distinct genetic makeup. Retrospective observational study in the EpiChron Cohort, selecting all the prevalent patients with breast cancer between 2010 and 2019. Logistic models were used to determine associated comorbidities. Between 2010 and 2019, 105 MBC and 11,657 FBC patients were found in the EpiChron Cohort. MBC patients had a high mean age at diagnosis and number of comorbidities. Paying attention to comorbidity prevalences in breast cancer patients, it was clear that MBC patients tended to be prone to cardio-metabolic coexisting diseases, while FBC patients were more prone to hormone-, bone- and mental diseases. There were nine chronic conditions associated to MBC patients, but after a year-by-birth matching only four associations remained. Two of them were associated previously [odds ratio (95% confidence interval)]: "Disorder of lipid metabolism" [1.65 (1.03-2.64)] and "Genitourinary symptoms and ill-defined conditions" [2.03 (1.07-3.87)]; and the other two were new, "Anxiety disorders" [2.05 (1.09-3.87)] and "Osteoporosis" [3.58 (1.26-10.14)]. After comparing associated comorbidities in FBC with those in MBC, it seems MBC patients share some of them, but they have their own particular set of coexisting diseases. In fact, once a year-by-birth matching was performed in MBC patient cohort, it was more obvious MBC comorbidities behave more similar to none-Breast-Cancer male population than to FBC patients. These findings highlight the distinct characteristics of the MBC patient population and the need for a tailored approach of managing MBC.
Identifiants
pubmed: 39362912
doi: 10.1038/s41598-024-73032-4
pii: 10.1038/s41598-024-73032-4
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
22977Informations de copyright
© 2024. The Author(s).
Références
Zheng, G. et al. Familial associations of male breast cancer with other cancers. Breast Cancer Res. Treat.166, 897–902 (2017).
doi: 10.1007/s10549-017-4468-1
pubmed: 28836035
Yao, N. et al. Clinicopathologic characteristics and prognosis for male breast cancer compared to female breast cancer. Sci. Rep. [Internet] (2022). https://doi.org/10.1038/s41598-021-04342-0
doi: 10.1038/s41598-021-04342-0
pubmed: 36581663
Shimomura, A. et al. Clinicopathological features of male patients with breast cancer based on a nationwide registry database in Japan. Breast Cancer29, 985–992 (2022).
doi: 10.1007/s12282-022-01378-6
pubmed: 35733033
Zheng, G. & Leone, J. P. Male breast cancer: An updated review of epidemiology, clinicopathology, and treatment. Breast Cancer [Internet] (2022). https://doi.org/10.1155/2022/1734049
doi: 10.1155/2022/1734049
pubmed: 36628811
Longo, D. L. & Giordano, S. H. Breast Cancer in Men. N. Engl. J. Med.378, 2311–2320 (2018).
doi: 10.1056/NEJMra1707939
Hassett, M. J. et al. Management of male breast cancer: ASCO guideline. J. Clin. Oncol.38, 1849–1863 (2020).
doi: 10.1200/JCO.19.03120
pubmed: 32058842
Leon-Ferre, R. A. et al. A contemporary review of male breast cancer: Current evidence and unanswered questions. Cancer Metastas. Rev.37, 4 (2018).
Johansson, I. et al. Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies N-acetyltransferase-1 (NAT1) as a novel prognostic biomarker. Breast Cancer Res. BCR [Internet] (2012).
Bender, P. F. M. et al. Men and women show similar survival rates after breast cancer. J. Cancer Res. Clin. Oncol.143, 563–571 (2017).
doi: 10.1007/s00432-016-2311-4
pubmed: 27933394
Konishi, T. et al. Comparison of short-term surgical outcomes between men and women with breast cancer: A retrospective study using nationwide inpatient data in Japan. Breast Cancer Res. Treat.186, 731–739 (2021).
doi: 10.1007/s10549-020-06069-4
pubmed: 33398479
Elimimian, E. B. et al. Male breast cancer: A comparative analysis from the national cancer database. World J. Men’s Health [Internet] (2021).
McClurg, D. P. et al. Analysis of the clinical advancements for BRCA-related malignancies highlights the lack of treatment evidence for BRCA-positive male breast cancer. Cancers (Basel). 14, 3175 (2022).
doi: 10.3390/cancers14133175
pubmed: 35804947
Calip, G. S. et al. Family history of breast cancer in men with non-BRCA male breast cancer: Implications for cancer risk counseling. Breast Cancer Res. Treat.185, 195–204 (2021).
doi: 10.1007/s10549-020-05922-w
pubmed: 32918117
Yadav, S. et al. Male breast cancer in the United States: Treatment patterns and prognostic factors in the 21st century. Cancer. 126, 26–36 (2020).
doi: 10.1002/cncr.32472
pubmed: 31588557
Oke, O., Niu, J., Chavez-MacGregor, M., Zhao, H. & Giordano, S. H. Adjuvant tamoxifen adherence in men with early-stage breast cancer. Cancer. 128, 59–64 (2022).
doi: 10.1002/cncr.33899
pubmed: 34597415
Konduri, S., Singh, M., Bobustuc, G., Rovin, R. & Kassam, A. Epidemiology of male breast cancer. Breast. 54, 8–14 (2020).
doi: 10.1016/j.breast.2020.08.010
pubmed: 32866903
Lin, A. P., Huang, T. W. & Tam, K. W. Treatment of male breast cancer: Meta-analysis of real-world evidence. Br. J. Surg.108, 1034–1042 (2021).
doi: 10.1093/bjs/znab279
pubmed: 34476472
Parise, C. A. & Caggiano, V. The association of race/ethnicity in male breast cancer survival within similar comorbidity cohorts. Cancer. 129, 750–763 (2023).
doi: 10.1002/cncr.34592
pubmed: 36597579
Ellington, T. D., Henley, S. J., Wilson, R. J. & Miller, J. W. Breast cancer survival among males by race, ethnicity, age, geographic region, and stage—United States, 2007–2016. MMWR Morb. Mortal. Wkly. Rep.69, 1481–1484 (2020).
doi: 10.15585/mmwr.mm6941a2
pubmed: 33056954
Sarmiento, S. et al. Male breast cancer: A closer look at patient and tumor characteristics and factors that affect survival using the National Cancer Database. Breast Cancer Res. Treat.180, 471–479 (2020).
doi: 10.1007/s10549-020-05556-y
pubmed: 32040687
Zoorob, R. J., Salemi, J. L., Mejia de Grubb, M. C., Modak, S. & Levine, R. S. A nationwide study of breast cancer, depression, and multimorbidity among hospitalized women and men in the United States. Breast Cancer Res. Treat.174, 237–248 (2019).
doi: 10.1007/s10549-018-5059-5
pubmed: 30465155
Hung, M. H. et al. Risk of second non-breast primary cancer in male and female breast cancer patients: A population-based cohort study. PLoS ONE. 11, 1–12 (2016).
doi: 10.1371/journal.pone.0148597
Linehan, E. S., Samant, N. D. & Rabbani, J. W. Examining racial disparities in male breast cancer. J. Clin. Oncol.39, 6555–6555 (2021).
doi: 10.1200/JCO.2021.39.15_suppl.6555
Liu, F. C. et al. Epidemiology and survival outcome of breast cancer in a nationwide study. Oncotarget. 8, 16939–16950 (2017).
doi: 10.18632/oncotarget.15207
pubmed: 28199975
Reiner, A. S., Navi, B. B., DeAngelis, L. M. & Panageas, K. S. Increased risk of arterial thromboembolism in older men with breast cancer. Breast Cancer Res. Treat.166, 903–910 (2017).
doi: 10.1007/s10549-017-4433-z
pubmed: 28836029
Sun, H. F. et al. Clinicopathological characteristics and survival outcomes of male breast cancer according to race: A SEER population-based study. Oncotarget. 8, 69680 (2017).
doi: 10.18632/oncotarget.18265
pubmed: 29050233
Prados-Torres, A. et al. Cohort profile: The epidemiology of chronic diseases and multimorbidity. The EpiChron Cohort Study. Int. J. Epidemiol.47, 382e–4e (2018).
doi: 10.1093/ije/dyx259
Ancín Ducay, J. M., Erce Lopez, S., Extramiana Cameno, E. & Izcue Argandoña, A. Correlación de códigos CIE-9-MC (8
Agency for Healthcare Research and Quality. Clinical Classifications Software (CCS) for ICD-9-CM [Internet]. Healthcare Cost and Utilization Project (HCUP). 2015 [cited 2023 Aug 1]. www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp
Chronic Condition. Indicator (CCI) for ICD-9-CM [Internet]. [cited 2023 Aug 24]. https://hcup-us.ahrq.gov/toolssoftware/chronic/chronic.jsp
Thuler, L. C. S. & Bergmann, A. Male breast cancer: Clinical-epidemiological characteristics of 1189 Brazilian patients. Aging Male. 18, 118–123 (2015).
doi: 10.3109/13685538.2014.922532
pubmed: 24871582
Han, H. et al. Hypertension and breast cancer risk: A systematic review and meta-analysis. Sci. Rep.7, 44877 (2017).
doi: 10.1038/srep44877
pubmed: 28317900
Dinapoli, L., Colloca, G., Di Capua, B. & Valentini, V. Psychological aspects to consider in breast cancer diagnosis and treatment. Curr. Oncol. Rep.23, 38 (2021).
doi: 10.1007/s11912-021-01049-3
pubmed: 33709235
Rachner, T. D., Coleman, R., Hadji, P. & Hofbauer, L. C. Bone health during endocrine therapy for cancer. Lancet Diabetes Endocrinol.6, 901–910 (2018).
doi: 10.1016/S2213-8587(18)30047-0
pubmed: 29572126
Liu, W. et al. Dysregulated cholesterol homeostasis results in resistance to ferroptosis increasing tumorigenicity and metastasis in cancer. Nat. Commun.12, 5103 (2021).
doi: 10.1038/s41467-021-25354-4
pubmed: 34429409
González-Ortiz, A., Galindo-Hernández, O., Hernández-Acevedo, G. N., Hurtado-Ureta, G. & García-González, V. Impact of cholesterol-pathways on breast cancer development, a metabolic landscape. J. Cancer. 12, 4307–4321 (2021).
doi: 10.7150/jca.54637
pubmed: 34093831
Zipinotti dos Santos, D. et al. The impact of lipid metabolism on breast cancer: A review about its role in tumorigenesis and immune escape. Cell. Commun. Signal.21, 161 (2023).
doi: 10.1186/s12964-023-01178-1
pubmed: 37370164
Karlsson, C. T., Malmer, B., Wiklund, F. & Grönberg H. Breast cancer as a second primary in patients with prostate cancer—estrogen treatment or association with family history of cancer? J. Urol.176, 538–543 (2006).
doi: 10.1016/j.juro.2006.03.036
pubmed: 16813884
Chung, C. P., Behrendt, C., Wong, L., Flores, S. & Mortimer, J. E. Serial Assessment of urinary incontinence in breast Cancer survivors undergoing (neo)adjuvant therapy. J. Natl. Compr. Canc. Netw.18, 712–716 (2020).
doi: 10.6004/jnccn.2020.7535
pubmed: 32502980
Greif, J. M., Pezzi, C. M., Klimberg, V. S., Bailey, L. & Zuraek, M. Gender differences in breast cancer: Analysis of 13,000 breast cancers in men from the National Cancer Data Base. Ann. Surg. Oncol.19, 3199–3204 (2012).
doi: 10.1245/s10434-012-2479-z
pubmed: 22766989
Scomersi, S. et al. Comparison between male and female breast cancer survival using propensity score matching analysis. Sci. Rep.11, 11639 (2021).
doi: 10.1038/s41598-021-91131-4
pubmed: 34079019
Land, L. H., Dalton, S. O., Jensen, M-B. & Ewertz, M. Impact of comorbidity on mortality: A cohort study of 62,591 Danish women diagnosed with early breast cancer, 1990–2008. Breast Cancer Res. Treat.131, 1013–1020 (2012).
doi: 10.1007/s10549-011-1819-1
pubmed: 22002567
Wang, X. et al. Prognostic value of depression and anxiety on breast cancer recurrence and mortality: A systematic review and meta-analysis of 282,203 patients. Mol. Psychiatry. 25, 3186–3197 (2020).
doi: 10.1038/s41380-020-00865-6
pubmed: 32820237
Parise, C. A. & Caggiano, V. The influence of comorbidity on treatment and survival of triple-negative breast cancer. Breast J.26, 1729–1735 (2020).
doi: 10.1111/tbj.13924
pubmed: 32488903
Dumas, E. et al. Concomitant medication, comorbidity and survival in patients with breast cancer. Nat. Commun.15, 2966 (2024).
doi: 10.1038/s41467-024-47002-3
pubmed: 38580683